河北医科大学学报 ›› 2022, Vol. 43 ›› Issue (11): 1328-1332.doi: 10.3969/j.issn.1007-3205.2022.11.018

• • 上一篇    下一篇

系统性红斑狼疮患者血清PS-PLA1、CCL19、IL-17、IL-23表达水平与病情活动度的相关性分析

  

  1. 河北省保定市第一中心医院医学检验科，河北 保定 071000

  • 出版日期:2022-11-25 发布日期:2022-12-28
  • 作者简介:杜亚涛（1978-），男，河北安国人，河北省保定市第一中心医院主管技师，医学硕士，从事医学检验诊断研究。
  • 基金资助:
    河北省自然科学基金项目（H2021104017）

Correlation analysis of expression levels of serum PS-PLA1, CCL19, IL-17, IL-23 and disease activity in patients with systemic lupus erythematosus

  1. Department of Medical Laboratory, the First Central Hospital of Baoding City, Hebei Province, Baoding 071000, China
  • Online:2022-11-25 Published:2022-12-28

HTML

PDF (PC)

94

摘要： 目的 分析系统性红斑狼疮患者血清磷脂酰丝氨酸特异性磷脂酶A1（serum phosphatidylserine-specific phospholipase A1，PS-PLA1）、趋化因子配体19（chemokine ligand 19，CCL19）、白细胞介素17（interleukin-17，IL-17）、白细胞介素23（interleukin-23，IL-23）表达水平与病情活动度的相关性。
方法 回顾性收集系统性红斑狼疮患者103例的临床资料，根据患者系统性红斑狼疮疾病活动度评分（systemic lupus erythematosus disease activity score，SLEDAI）将其分为轻度亚组（31例）、中度亚组（50例）、重度亚组（22例），另选择同期健康体检人群62例作为对照组。比较研究组和对照组血常规［白细胞计数（white blood cell count，WBC）、淋巴细胞百分比（lymphocyte percentage，LY%）、血小板（platelet ，PLT）、血红蛋白（hemoglobin，Hb）］及免疫功能［血清免疫球蛋白G（immunoglobulin G，IgG）、免疫球蛋白A（immunoglobulin A，IgA）、免疫球蛋白M（immunoglobulin M，IgM）、补体C3、补体C4］相关指标水平，比较研究组和对照组、各亚组血清PS-PLA1、CCL19、IL-17、IL-23水平。通过Pearson相关性分析法分析PS-PLA1、CCL19、IL-17、IL-23与血常规、免疫功能相关指标的相关性。
结果 研究组全血WBC、LY%、PLT、Hb、补体C3、补体C4水平低于对照组，血清IgG、IgA、IgM水平高于对照组（P＜0.05）。研究组血清PS-PLA1、CCL19、IL-17、IL-23水平高于对照组（P＜0.05）。重度亚组血清PS-PLA1、CCL19、IL-17、IL-23水平高于轻度亚组、中度亚组，中度亚组血清PS-PLA1、CCL19、IL-17、IL-23水平高于轻度亚组（P＜0.05）。Pearson相关性分析法结果显示，PS-PLA1与IgG表达呈正相关（P＜0.05），CCL19、IL-17、IL-23与IgG、IgA、IgM表达呈正相关（P＜0.05），IL-17、IL-23与补体C3表达呈负相关（P＜0.05）。
结论 系统性红斑狼疮患者血清PS-PLA1、CCL19、IL-17、IL-23水平升高，且其水平与患者病情活动度及细胞免疫功能障碍有关，可能作为系统性红斑狼疮临床诊治的新靶点。


关键词: 红斑狼疮,系统性, 白细胞介素17, 白细胞介素23

Abstract: Objective To analyze the correlation between expression levels of serum phosphatidylserine-specific phospholipase A1(PS-PLA1), chemokine ligand 19(CCL19), interleukin-17(IL-17), and interleukin-23(IL-23) and disease activity in patients with systemic lupus erythematosus(SLE). 
Methods Clinical data of 103 patients with SLE were collected retrospectively, and the patients were divided into the mild subgroups(n=31), the moderate subgroups(n=50), and the severe subgroup(n=22) according to the systemic lupus erythematosus disease activity score(SLEDAS). Another 62 people undergoing physical examination population during the same period were selected as the control group. The blood routine index ［white blood cell(WBC) count, lymphocyte percentage(LY%), platelet(PLT), hemoglobin(Hb)］ and immune function-related index ［immunoglobulin G(IgG), immunoglobulin A(IgA), immunoglobulin M(IgM), complement 3(C3), and complement 4(C4) ］ of the two groups were compared between two groups. The levels of serum PS-PLA1, CCL19, IL-17, and IL-23 between the research group and the control group as well as between each subgroup were analyzed, and the correlation of PS-PLA1, CCL19, IL-17, IL-23 and blood routine and immune function-related indexes was analyzed by Pearson correlation analysis method. 
Results The levels of complete blood WBC, LY%, PLT, Hb, C3, and C4 in the research group were lower than those of the control group, while the levels of serum IgG and IgA and IgM were higher than those of the control group(P＜0.05). The levels of serum PS-PLA1, CCL19, IL-17, and IL-23 in the research group were higher than those in the control group(P＜0.05). The levels of serum PS-PLA1, CCL19, IL-17, and IL-23 were higher in the severe subgroup than in the mild and moderate subgroups, and higher in moderate subgroup than in the mild subgroup(P＜0.05). The results of Pearson correlation analysis showed that PS-PLA1 and IgG expression were positively correlated(P＜0.05), CCL19, IL-17, IL-23 and IgG, IgA, IgM expressions were positively correlated(P＜0.05). and IL-17, IL-23 and C3 expression were negatively correlated(P＜0.05). 
Conclusion The levels of serum PS-PLA1, CCL19, IL-17 and IL-23 in patients with SLE are elevated, and their levels are closely related to the disease activity and cellular immune dysfunction, and may serve as new targets for the clinical diagnosis and treatment of SLE.


Key words: lupus erythematosus, systemic, interleukin-17, interleukin-23

版权所有 © 《河北医科大学学报》编辑部
本系统由北京玛格泰克科技发展有限公司设计开发